SEC Filing Summary: SIGA Technologies, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by SIGA Technologies, Inc. on November 18, 2016, covering events occurring on November 16, 2016. The filing details the successful completion of a rights offering and the funding of a loan facility.
Key Financial Metrics and Transactions
- Rights Offering Proceeds: Approximately $35.3 million in gross proceeds raised through the sale of 23,523,195 shares of common stock.
- Subscription Price: $1.50 per share.
- Backstop Fee: An additional 708,530 shares were issued to Backstop Parties (including MacAndrews & Forbes LLC) as a 5% fee, valued at $2.49 per share based on the November 16, 2016 closing price.
- Loan Funding: The Company funded a loan under a previously disclosed loan and security agreement.
- Use of Proceeds: Net proceeds from the rights offering, combined with loan proceeds and cash on hand, were utilized to satisfy a judgment against the Company by PharmAthene, Inc., due by November 30, 2016, under the Company's Third Amended Chapter 11 Plan.
Material Changes
The filing reports a significant increase in equity capital and cash liquidity resulting from the fully subscribed rights offering. The Company satisfied a material contingent liability (the PharmAthene judgment) using the newly raised capital. No prior comparable period financial metrics (revenue, profit, margins) are provided in this specific filing.
Outlook, Risks, and Contingencies
The primary contingency addressed was the PharmAthene, Inc. judgment, which the Company has now funded. The backstop agreement with the Backstop Parties was not required to be drawn upon as the offering was fully subscribed. The filing does not contain forward-looking guidance on revenue or earnings.
Investor Verification Checklist
- Verify the final share count and total capital raised including the backstop fee shares.
- Confirm the full satisfaction of the PharmAthene, Inc. judgment by the November 30, 2016 deadline.
- Review the terms of the funded loan agreement disclosed in the September 7, 2016 8-K.
- Assess the impact of the new share issuance on existing shareholder dilution.